Business Development & Strategy Director for The HH Group. Founder and Director of BridgePointAI, the commercial advisory firm partnering with HH to drive its growth strategy. The appointment establishes an ongoing commercial partnership between the HH Group and BridgePointAI, following a successful discovery phase.

Mark leads commercial strategy, client development, and pipeline growth across HH's three operating companies, HH Research & Innovation, HH Data & Evidence Services, and HH Insight. His remit covers commercialisation pathways, ecosystem partnerships, and go-to-market design for regulated, high-risk environments.

He brings strategic growth and commercial expertise across the technology and healthcare sectors. Previously holding senior roles at GSK, Haleon, BP, and Rolls-Royce Aerospace, Mark has led commercialisation pathways, ecosystem development, and go-to-market strategy for product, platform, and infrastructure businesses operating under regulatory scrutiny.

Focus areas: Commercial strategy, partnership architecture, GTM design, ecosystem development, and pipeline growth in regulated science and technology sectors.

Through BridgePointAI: Advises portfolio companies on commercial readiness, partnership architecture, and growth strategy across health, technology, and energy sectors.

"Mark brings strategic growth and commercial expertise across technology and healthcare sectors, he has led commercialisation pathways, ecosystem development, and go-to-market strategy for regulated, high-risk environments. The HH Group is pleased to formalise the partnership."

— The HH Group, on Mark's appointment